Trevi Therapeutics (NASDAQ:TRVI) Receives “Buy” Rating from HC Wainwright

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $12.50 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 89.11% from the company’s current price.

TRVI has been the subject of several other reports. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $9.00 to $29.00 in a report on Monday, March 10th. Needham & Company LLC cut their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday. Oppenheimer lifted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, March 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a report on Wednesday. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $17.56.

Trevi Therapeutics Trading Down 2.9 %

TRVI opened at $6.61 on Wednesday. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39. The firm has a market capitalization of $508.08 million, a PE ratio of -15.02 and a beta of 0.90. The firm has a 50 day moving average of $4.55 and a two-hundred day moving average of $3.73.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Activity at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total value of $548,862.75. Following the sale, the insider now directly owns 76,900 shares in the company, valued at approximately $519,075. The trade was a 51.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 24.37% of the stock is owned by insiders.

Institutional Trading of Trevi Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TRVI. GSA Capital Partners LLP purchased a new stake in Trevi Therapeutics during the third quarter worth about $409,000. Oppenheimer & Co. Inc. increased its stake in Trevi Therapeutics by 34.7% during the third quarter. Oppenheimer & Co. Inc. now owns 81,947 shares of the company’s stock worth $274,000 after purchasing an additional 21,128 shares during the period. MAI Capital Management increased its stake in Trevi Therapeutics by 0.7% during the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after purchasing an additional 8,789 shares during the period. Intech Investment Management LLC purchased a new stake in Trevi Therapeutics during the third quarter worth about $63,000. Finally, BNP Paribas Financial Markets increased its stake in Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares during the period. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.